REG - RTW Biotech Opp. - Kailera Reports Positive Data in Ph2 Obesity Trial

RTW Biotech OpportunitiesAnnouncement

27/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250127:nRSa6830Ua&default-theme=true

RNS Number : 6830U  RTW Biotech Opportunities Ltd  27 January 2025

LEI: 549300Q7EXQQH6KF7Z84

27 January 2025

RTW Biotech Opportunities Ltd

Kailera Announces Positive Data in Phase 2 Obesity Trial

RTW Biotech Opportunities Ltd (the "Company", "RTW Bio"), a London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note an announcement from portfolio company, Kailera Therapeutics
("Kailera"), a clinical-stage biopharmaceutical company focused on advancing a
broad pipeline of next-generation therapies for the treatment of obesity and
related conditions.

 

On 13 January, Kailera announced positive topline data from the 8 mg dose of
Hengrui Pharmaceutical's Phase 2 clinical trial (HRS9531-203) of HRS9531, a
GLP-1/GIP receptor dual agonist, in individuals living with obesity or
overweight. The clinical trial results showed that a once-weekly subcutaneous
injection of the 8 mg dose of HRS9531 demonstrated a statistically significant
21.1% (p<0.0001) placebo-adjusted mean weight loss (22.8% mean change from
baseline) at week 36, with no plateau in weight loss. Additionally, 59% of
HRS9531-treated participants achieved a weight loss of ≥20%. The trial
results also demonstrated a favourable safety profile. Most adverse events
were mild and consistent with the profile reported for the injectable
GLP-1/GIP receptor dual agonist class.

 

Roderick Wong, Managing Partner and CIO at RTW Investments, LP, the Investment
Manager ("RTW") said, "With 22.8% weight loss at 36 weeks, HRS9531 looks like
a potentially best-in-class treatment for obesity and related conditions,
beating the 21% shown by Eli Lilly's retatrutide. These data increase our
confidence that Kailera is one of the leading players in next-generation
obesity management. Obesity is a major risk factor for a number of chronic
diseases like diabetes, hypertension and liver disease, as well as
cardiovascular diseases such as heart disease and stroke, which are the
leading causes of death worldwide and, as such, the treatment of it is a core
focus for us."

 

The full text of the announcement can be accessed at

https://www.kailera.com/press-release/jiangsu-hengrui-pharmaceuticals-and-kailera-therapeutics-report-positive-topline-data-from-8-mg-dose-of-phase-2-obesity-trial-of-glp-1-gip-receptor-dual-agonist-hrs9531/
(https://www.kailera.com/press-release/jiangsu-hengrui-pharmaceuticals-and-kailera-therapeutics-report-positive-topline-data-from-8-mg-dose-of-phase-2-obesity-trial-of-glp-1-gip-receptor-dual-agonist-hrs9531/)

 

If you want to learn more about RTW's views on the science, impact, evolving
competitive landscape and investment opportunities within obesity management
and related conditions, then you can do so via The RTW Podcast Episode 3: "The
$1 Trillion GLP-1 Revolution". You can find it on all the main podcast
platforms and in the Content & Media section of RTW Bio's website:

https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/content-media/
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/content-media/)

 

 

For Further Information

 RTW Investments, LP                                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development                  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Cadarn Capital (PR & Communications/Distribution & IR Partner)           +44 79 8418 4461
                                                                           Lucy@cadarncapital.com (mailto:Lucy@cadarncapital.com)

 Lucy Clark (PR)

 David Harris (Distribution)                                              +44 73 6888 3211

                                                                          david@cadarncapital.com

 Deutsche Numis (Joint Corporate Broker)                                  +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities (Joint Corporate Broker)                                 +44 20 7628 1000

 Edward Peel

 Alex Penney

 Elysium Fund Management Limited                                           +44 14 8170 3100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                                     +1 914 225 8885

 

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBRGDBIGDDGUS